Geode Capital Management
FLGT icon

Geode Capital Management’s Fulgent Genetics FLGT Stock Holding History

Geode Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
521,014
-63,193
-11% -$1.07M ﹤0.01% 2499
2026
Q1 		$9.29M Buy
584,207
+75,983
+15% +$1.65M ﹤0.01% 2423
2025
Q4 		$13.4M Buy
508,224
+6,553
+1% +$170K ﹤0.01% 2251
2025
Q3 		$11.3M Sell
501,671
-11,672
-2% -$240K ﹤0.01% 2348
2025
Q2 		$10.2M Buy
513,343
+8,105
+2% +$158K ﹤0.01% 2353
2025
Q1 		$8.54M Sell
505,238
-8,914
-2% -$152K ﹤0.01% 2388
2024
Q4 		$9.5M Buy
514,152
+11,283
+2% +$220K ﹤0.01% 2412
2024
Q3 		$10.9M Buy
502,869
+13,320
+3% +$298K ﹤0.01% 2326
2024
Q2 		$9.61M Buy
489,549
+17,168
+4% +$358K ﹤0.01% 2344
2024
Q1 		$10.3M Buy
472,381
+9,621
+2% +$239K ﹤0.01% 2318
2023
Q4 		$13.4M Buy
462,760
+20,070
+5% +$537K ﹤0.01% 2159
2023
Q3 		$11.8M Buy
442,690
+30,183
+7% +$1.03M ﹤0.01% 2158
2023
Q2 		$15.3M Buy
412,507
+7,843
+2% +$273K ﹤0.01% 2040
2023
Q1 		$12.6M Buy
404,664
+9,134
+2% +$294K ﹤0.01% 2107
2022
Q4 		$11.8M Sell
395,530
-650
-0.2% -$23.3K ﹤0.01% 2144
2022
Q3 		$15.1M Buy
396,180
+13,222
+3% +$663K ﹤0.01% 1948
2022
Q2 		$20.9M Buy
382,958
+7,014
+2% +$385K ﹤0.01% 1741
2022
Q1 		$23.5M Buy
375,944
+1,733
+0.5% +$114K ﹤0.01% 1792
2021
Q4 		$37.6M Buy
374,211
+14,369
+4% +$1.26M ﹤0.01% 1515
2021
Q3 		$32.4M Buy
359,842
+23,963
+7% +$2.18M ﹤0.01% 1641
2021
Q2 		$31M Buy
335,879
+67,971
+25% +$5.43M ﹤0.01% 1678
2021
Q1 		$25.9M Buy
267,908
+71,596
+36% +$7.39M ﹤0.01% 1708
2020
Q4 		$10.2M Buy
196,312
+40,933
+26% +$1.71M ﹤0.01% 2170
2020
Q3 		$6.22M Sell
155,379
-858
-0.5% -$26.9K ﹤0.01% 2265
2020
Q2 		$2.5M Buy
156,237
+59,131
+61% +$905K ﹤0.01% 2721
2020
Q1 		$1.04M Buy
97,106
+3,313
+4% +$46.1K ﹤0.01% 3005
2019
Q4 		$1.21M Buy
93,793
+63,020
+205% +$749K ﹤0.01% 3212
2019
Q3 		$319K Buy
+30,773
New +$292K ﹤0.01% 3625
2017
Q2 		– Sell
-15,051
Closed -$164K – 4091
2017
Q1 		$164K Buy
15,051
+1,238
+9% +$14.6K ﹤0.01% 3712
2016
Q4 		$159K Buy
+13,813
New +$130K ﹤0.01% 3688

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management's FLGT Position: Q2 2026 in Review

Geode Capital Management reduced its Fulgent Genetics (FLGT) stake by 11% in Q2 2026, selling an estimated $1.07M and leaving 521,014 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

Geode Capital Management first reported a position in FLGT in Q4 2016 and has held it in 30 quarters since. The position peaked at $37.6M in Q4 2021. 125 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Geode Capital Management held 521,014 shares of Fulgent Genetics worth $10.7M as of Q2 2026.
  • Geode Capital Management sold 63,193 Fulgent Genetics shares in Q2 2026, an estimated $1.07M.
  • Fulgent Genetics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2499 holding.
  • Geode Capital Management first reported a position in Fulgent Genetics in Q4 2016 and has held it in 30 quarters since.
  • Geode Capital Management's Fulgent Genetics position peaked at $37.6M in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.